Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05 2018 - 4:30PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of
inducement stock options to three new employees for an aggregate of
20,600 shares of common stock. The Compensation Committee of the
Board of Directors approved the grants with an effective date of
October 1, 2018. The stock options have an exercise price of $18.14
per share and were granted as inducements material to the employees
entering into employment with the Company in accordance with Nasdaq
Listing Rule 5635(c)(4).
The stock options vest over four years, with 25% of the shares
vesting on the one-year anniversary of the applicable vesting
commencement date and 1/48 of the shares vesting monthly
thereafter, subject to the new employee's continued service
relationship with the Company. The stock options are subject to the
terms and conditions of the Company's 2013 Equity Incentive Plan
and a stock option agreement pursuant to which the stock option was
granted.
About Flexion Therapeutics Flexion Therapeutics
(Nasdaq:FLXN) is a biopharmaceutical company focused on the
development and commercialization of novel, local therapies for the
treatment of patients with musculoskeletal conditions, beginning
with osteoarthritis, a type of degenerative arthritis. The
company's core values are focus, ingenuity, tenacity, transparency
and fun. For the past two years, Flexion has been named one of the
Best Places to Work by the Boston Business Journal, and
Flexion was also recognized as a Top Place to Work in Massachusetts
by The Boston Globe in 2017.
Contact:Scott YoungVice President, Corporate
Communications & Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024